Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018 — Myeloma Research News

Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with relapsed or refractory disease, updated Phase 1 data is expected to show. An earlier analsyis showed that, among patients receiving doses of 150 million cells or higher, 94 percent responded to the treatment, including 56…

via Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018 — Myeloma Research News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.